Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

More SCOTUS fallout: Appeals court revives Lamictal pay-for-delay fight against GSK, Teva

In the post- FTC v. Actavis  world, cash doesn't have to change hands for a pay-for-delay deal to fall afoul of antitrust law. That's becoming clear as court rulings pile up. And a new U.S. appeals court decision specifically addresses a branded drugmaker's agreement not to launch an authorized generic of its branded drug.

CDC panel disappoints Pfizer, GSK with limited backing for meningitis B shots

The CDC's Advisory Committee for Immunization Practices gave the go-ahead for wider use of meningitis B vaccines, but stopped short of a universal recommendation, not the result many--including GlaxoSmithKline and Pfizer--were hoping to see.

ACIP gives Glaxo, Pfizer a lukewarm decision for new meningitis B vaccines

The CDC's Advisory Committee on Immunization Practices (ACIP) voted on Wednesday to expand its recommendation for meningitis B vaccines, but it wasn't the broad recommendation that many were hoping to see.

Pfizer to acquire GlaxoSmithKline meningitis vaccines for $130M

In a move to allay antitrust concerns, GlaxoSmithKline is selling two of its meningitis vaccines to Big Pharma peer Pfizer. The move comes after Glaxo acquired the bulk of Novartis' vaccines portfolio, which catapulted it to the No. 1 spot in the global vaccines market.

FierceBiotech Radio at #BIO2015

FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.

Video: Blazing a short path to an accelerated approval in oncology

At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.

Merck, GSK, Sanofi and Pfizer will vie for crown in tight vaccines race by 2020: Report

Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says.

GlaxoSmithKline takes another big swing at cancer drug R&D

GlaxoSmithKline still has big plans in the burgeoning field of cancer drug R&D. And one of the pharma giant's top cancer drug R&D execs says Glaxo is ready to strike new deals to beef up the pipeline as it considers rebuilding a late-stage research effort and new commercial operations to support marketing the most successful drugs to come out of it.

Novartis zeroes in on costs as blockbusters-to-be Cosentyx, Entresto rev up

Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.

Researchers say compound stops transmission of malaria parasite in mice

Researchers in Australia say a compound tested in mice kills the parasite that causes malaria. They hope to move a candidate they estimate would cost around $1 a dose into human clinical trials, according to an abstract published in the journal Nature.